+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Drug Discovery Informatics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

  • PDF Icon


  • 120 Pages
  • June 2022
  • Region: Global
  • Mordor Intelligence
  • ID: 4787519
The Drug Discovery Informatics Market is poised to grow at a CAGR of 15.3% during the forecast period, 2022-2027.

Amid the COVID-19 pandemic, the health systems of countries have been heavily investing in research and development to combat the virus. Research groups across the world have set about identifying small molecule drugs for the treatment of COVID-19, Thus, in view of the ongoing pandemic, the drug discovery of drugs increases thereby rising demand for the drug discovery bioinformatics market. According to the study titled "A critical overview of computational approaches employed for COVID-19 drug discovery" in the journal of Chemical Society Review in August 2021, Much of the research effort has focused on the discovery of novel drug candidates or repurposing of existing drugs against COVID-19. researcher posits that truly impactful computational tools must deliver actionable, experimentally testable hypotheses enabling the discovery of novel drugs and drug combinations and that open science and rapid sharing of research results are critical to accelerating the development of novel, much needed therapeutics for COVID-19. Thus, drug discover information market significantly impacted by the COVID-19.

Certain factors driving the market growth include high R&D expenditure by pharmaceutical and biotechnology companies for drug discovery and development , increasing technological advancement in data mining and analytics. According to 2021 Annual report of Novartis, Novartis invested approximately USD 59 million in neglected disease research and development in 2021, as defined by the Access to Medicine Foundation as R&D priority areas. As a result of this investment many diseases previously regarded as deadly are now manageable and even curable and this trend is expected to continue which will drive the growth of the studied market in the country. Additionally , according to Congressional Budget Office in April 2021, the pharmaceutical sector spent USD 83 billion on research and development in 2019. Inflation-adjusted, that sum is around ten times what the industry spent every year in the 1980s. Rising investment in research and development will in turn increase the need for toxicology screening services, thereby propelling the growth of the market.

However, various small and medium pharma raises the funding for drug discovery and development anticipated to boost the market. For instance, in March 2022, ArrePath, a drug discovery startup, raised USD 20 million in a seed funding round led by the Boehringer Ingelheim Venture Fund, Insight Partners, and Innospark Ventures. The investment will be used to support the company's machine learning-based drug discovery platform, which focuses on developing new types of anti-infective drugs to combat antimicrobial resistance.

Morever, increasing technological advancement in the drug discovery platforms expected to grow the market over the forecast period. For instance in October 2021, PyTorch has released of its machine learning drug discovery platform TorchDrug to accelerate drug discovery research. The library is open-sourced and can be installed through pip if you have PyTorch and torch-scatter installed using pip install torchdrug, or through conda conda install -c milagraph -c conda-forge torchdrug.

Thus, all aforementioned factors anticipated to boost the market, However, high pricing and setup cost for infomatics software restraint the market over the forecast period.

Key Market Trends

Pharmaceutical and Biotechnology Companies are Expected to Grow with High CAGR in the Forecast Period

Pharmaceutical companies are heavily relying on this informatics software for pre-clinical research and development, target identification, compound screening, and lead identification, as well as streamlining their drug discovery process, which is a major factor driving this segment's growth. Informatics analysis in drug discovery not only accelerates drug target identification and drug candidate screening and refinement but also facilitates the characterization of side effects and predicts drug resistance. Researchers and the pharmaceutical industry can use data mining software for drug discovery to gain access to all relevant and up-to-date data generated by the scientific community.

However, product launches by pharmaceutical companies are anticipated to grow the segment over the forecast period. For instance, in December 2020, Curve Therapeutics Ltd. used the CDD Vault platform to manage its platform, which is genetically encoded. It's a cloud-based platform that's suitable for pharmaceutical and biotechnology applications, allowing for the secure and seamless sharing of data in real-time, allowing for collaborative discoveries.

The Various strategies adopted by the pharma players to bolster the used of drug discovery informatics in drug discovery, drug design and drug development. For instance, In April 2022, Iktos, a company specialized in Artificial Intelligence (AI) for new drug design, and Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business that provides comprehensive healthcare services to improve the quality of life, reported a strategic collaboration agreement in Artificial Intelligence for small molecules drug discovery.

Similarly, in January 2022, Shanghai Fosun Pharmaceutical (Fosun Pharma), a China-based healthcare group, and Insilico Medicine, a US-based artificial intelligence (AI)-driven drug discovery and development company, entered into a collaboration agreement to advance the discovery and development of drugs targeting a number of different targets globally using AI technology.

Thus, all aforementioned factors anticipated boosting the segment growth over the forecast period.

North America Dominates the Market and is Expected to do Same Over the Forecast Period

North America is expected to dominate the overall market, throughout the forecast period. In the North American region, the United States holds the largest market share and this is due to the increasing R&D on drug discovery and technological advancements in data mining and analytics. This has helped the growth of the drug discovery informatics market in the country.

According to a report published in September 2021 by the Pharmaceutical Research and Manufacturers of America (PhRMA), in the last decade, biopharmaceutical companies invested more than a trillion dollars in research and development, including a record-breaking year in 2020 where PhRMA member companies invested about USD 91 billion in the research and development.

Furthermore, the global acceleration of Covid-19 drug discovery is adding to the market's growth. Similarly, companies are developing a variety of web services and solutions to aid in the development of Covid-19 at various stages. For Instance, in June 2020, the IBM visual molecular explorer platform investigated a subset of the generated coronavirus-targeting molecules (SARS-CoV-2). The explorer's open-source sharing of AI-generated artefacts aided in the early stages of optimal medicine design.

In addition, companies in the region are concentrating their efforts on joint ventures and research collaborations, which will help the market grow in the coming years. In December 2020, Atomwise, one of the leader in using artificial intelligence (AI) for small-molecule drug discovery, unveiled its growing portfolio of emerging joint venture with A2i therapeutics, FutuRx companies with research programs spanning oncology, immunology, infectious disease, neuroscience and clotting disorders. Thus research collaboration for drug discovery create huge demand for drug discovery informatics anticipated to boost the market.

Thus, all aforementioned factors anticipated to boost the market growth over the forecast period.

Competitive Landscape

The drug discovery informatics market is competitive and consists of a few major players. In terms of market share, these major players currently dominate the market. Key players are increasingly collaborating with other companies, research institutes, and clinical research organizations to promote rapid drug development. Some of the major players in the market are Infosys, IBM, and PerkinElmer, Io informatics among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This product will be delivered within 2 business days.

Table of Contents

1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 Technological Advancements in Data Mining and Analytics
4.2.2 Increasing R&D on Drug Discovery
4.3 Market Restraints
4.3.1 High Pricing and Setup Cost of Informatics Software
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Function
5.1.1 Sequencing and Target Data Analysis
5.1.2 Docking
5.1.3 Molecular Modeling
5.1.4 Libraries and Database Preparation
5.1.5 Other Functions
5.2 By End User
5.2.1 Pharmaceutical and Biotechnology Companies
5.2.2 Contract Research Organizations (CROS)
5.2.3 Other End Users
5.3 Geography
5.3.1 North America United States Canada Mexico
5.3.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.3.3 Asia - Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.3.4 Middle East and Africa GCC South Africa Rest of Middle East and Africa
5.3.5 South America Brazil Argentina Rest of South America
6.1 Company Profiles
6.1.1 Collaborative Drug Discovery
6.1.2 Dassault System
6.1.3 IBM
6.1.4 Infosys
6.1.5 IO Informatics
6.1.6 Jubilant Life Sciences
6.1.7 Perkinelmer
6.1.8 Certara
6.1.9 Aragen Lifescience Pvt. Ltd
6.1.10 Selvita
6.1.11 Charles River Laboratories
6.1.12 Thermo Fisher Scientific

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Collaborative Drug Discovery
  • Dassault System
  • IBM
  • Infosys
  • IO Informatics
  • Jubilant Life Sciences
  • Perkinelmer
  • Certara
  • Aragen Lifescience Pvt. Ltd
  • Selvita
  • Charles River Laboratories
  • Thermo Fisher Scientific